Thyroid Guide · Hashimoto's at a glance

Hashimoto's at a Glance: Diagnosis, Course, Monitoring and Treatment

Positive antibodies are common; hypothyroidism that needs treatment is considerably rarer. What a result means, how Hashimoto's can develop, which check-ups guidelines recommend, and when levothyroxine is indicated.

SJ
Shukri Jarmoukli · Physician, Integrative Medicine · ViveCura Berlin
Antibodies, diagnosis, hypothyroidism kept apart Guidelines with setting and life stage Selenium, vitamin D, iron, gluten with level of evidence 57 checked sources, 53 with DOI
Why I am writing this

Hashimoto's is first of all a finding with a probability attached, not automatically a disease that needs tablets straight away. But if you do have the diagnosis, you deserve more than a number on a lab report: an understandable plan, good dose adjustment, and a look at what sits alongside it.

There it is on the report. TPO antibodies raised. And next to it a word you had only heard in passing: Hashimoto's.

Maybe it was mentioned casually. Maybe you read the printout alone in the evening. Then the searching begins: flare, tablets for life, wanting a baby.

Many people know this pattern. The more they read, the more unsettled they become. Not because everything is wrong, but because none of it is sorted.

This article sorts it. It separates the antibody result from hypothyroidism, shows what large cohorts say about the course, what guidelines recommend and where they contradict each other. And it gives an honest account of what selenium, vitamin D, iron and a gluten-free diet can contribute.

Why the immune system attacks the thyroid in the first place is covered in detail in Understanding Hashimoto's thyroiditis. Here the focus is on the practical questions that come after.

Before you read on

When you should not wait

Hashimoto's usually runs quietly. These signs still belong in medical hands promptly or immediately:

  • Racing heart, irregular pulse or chest pain, for example in an overactive phase or with too high a dose. With chest pain or shortness of breath: call 112 (the emergency number in Germany and across the EU).
  • Thoughts of not wanting to live any more, or persistent deep low mood: get help immediately. In Germany: Telefonseelsorge 0800 111 0 111 or 0800 111 0 222, around the clock and free of charge (these are German numbers; outside Germany, please use your local crisis line). In acute danger 112, the nearest psychiatric hospital or emergency department.
  • Marked slowing, confusion, severe sensitivity to cold with drowsiness: rare, but an emergency: 112.
  • Double vision, worsening sight, bulging or painful eyes: see an eye doctor immediately.
  • Rapidly growing nodule, hoarseness, difficulty swallowing or breathing: have it checked by a doctor promptly, with shortness of breath 112.
  • Fever with a painful thyroid: more likely a different form of thyroid inflammation.
  • Positive pregnancy test while on levothyroxine: inform your practice promptly, as the requirement can change early on.

And one sentence that stands above everything: No changes to levothyroxine, T3, natural thyroid preparations or antithyroid drugs on your own. Not to the dose, not to the preparation, not to the time you take it. Any change can shift the TSH value and belongs under medical supervision.

What to expect here

  • What Hashimoto's is and how common it is
  • Symptoms in women, in men, in menopause
  • Diagnosis, which doctor, why no home test is enough
  • Course, hashitoxicosis and what “flare” means
  • Treatment according to guidelines and correct intake
  • Check-ups and the cancer risk in numbers
  • Trying to conceive and pregnancy
  • Associated conditions and heredity
  • Selenium, vitamin D, iron, gluten, stress
  • 14 frequently asked questions
RCT / Meta randomised or pooled Human cohort, cross-sectional, twin study Guideline recommendation of a medical society Animal animal study, not cited here Lab test tube or cell culture

What Hashimoto's is, and three numbers that are often confused

Imagine the thyroid as a small workshop that builds hormones and keeps them in stock. In Hashimoto's, immune cells move into this workshop. They stay. And over years, tissue that produces hormones can be lost.

The medical name is chronic lymphocytic autoimmune thyroiditis. In regions with adequate iodine supply it is the most common cause of hypothyroidism, according to a recent Lancet seminar by Taylor and colleagues.

Hashimoto's is not one uniform picture. A review by Caturegli and colleagues describes several variants, including hashitoxicosis and painless thyroiditis, sporadic or after childbirth. Most forms lead into hypothyroidism, but at the start, function can be normal or even raised.

Three frequencies that do not measure the same thing

11.3 %positive TPO antibodies, US population aged 12 and over (NHANES III)
7.5 %Hashimoto's in adults worldwide, meta-analysis of 48 studies
0.3 %overt hypothyroidism in NHANES III, plus 4.3 % subclinical
Cross-sectional, n=17,353 Antibodies are more common than hypothyroidism

A team led by Hollowell examined 17,353 people aged 12 and over in the US health survey NHANES III for TSH, T4 and thyroid antibodies.

TPO antibodies were positive in 11.3 percent, Tg antibodies in 10.4 percent. Hypothyroidism was found in 4.6 percent, of which 0.3 percent clinical and 4.3 percent subclinical. TPO antibodies were associated with thyroid dysfunction; Tg antibodies alone, without TPO antibodies, were not.

For you this means: a positive antibody result is a risk marker that roughly one in nine people carries. It is not the same as hypothyroidism.

Hollowell JG, Staehling NW, Flanders WD, et al. J Clin Endocrinol Metab. 2002;87(2):489-99. PMID: 11836274 · DOI: 10.1210/jcem.87.2.8182 [Cross-sectional, n=17,353]

The second number comes from a meta-analysis of 48 studies by Hu and colleagues: 7.5 percent in adults, with wide variation, women about four times as often as men. Because the studies defined Hashimoto's differently, this is an order of magnitude, not an exact value.

Another way to see it

The three numbers cannot be combined, but together they tell you something reassuring: many people carry antibodies, considerably fewer develop overt hypothyroidism. A result is the beginning of observation, not a verdict.

And why does the immune system turn against the thyroid at all? Genes, iodine, smoking, pregnancy and the gut barrier are under discussion. That is covered in Hashimoto's and the immune system. And now you know why an antibody result on its own is not yet hypothyroidism.

Symptoms: what can be part of it, in women, in men and in menopause

Tired. Cold. Heavier than usual. Skin dry, head slow. You read the list of typical complaints and recognise yourself in almost every point.

That is exactly the difficulty. Fatigue, lack of drive, weight gain and sensitivity to cold are the classic complaints of hypothyroidism, but according to the Lancet seminar they are non-specific. The diagnosis is therefore usually made through lab values.

DEGAM, the German society of general practitioners, goes further. Because sensitivity and specificity are insufficient, its guideline makes no recommendation to ask specifically about “typical” complaints in order to confirm a diagnosis.

Cross-sectional, n=7,995 Mildly raised TSH, same symptom burden

A team led by Carlé compared 376 people with subclinical hypothyroidism with 7,619 people with normal thyroid function across three Danish population surveys, asking about 13 complaints.

The median symptom score was 2 in both groups (interquartile range 0 to 4), P = 0.25. Other illnesses had the greatest influence; the level of TSH had none.

For you this means: complaints with a mildly raised TSH are not imagined. But they may have other causes, and those deserve a search.

Carlé A, Karmisholt JS, Knudsen N, et al. Am J Med. 2021;134(9):1115-1126.e1. PMID: 33872585 · DOI: 10.1016/j.amjmed.2021.03.009 [Cross-sectional, n=7,995]

This fits with the TRUST trial by Stott and colleagues: in 737 people aged 65 and over with subclinical hypothyroidism, one year of levothyroxine showed no difference from placebo in the symptom score; this cannot be transferred to younger people or high TSH values.

Women: the cycle

In women, hypothyroidism can show up in the menstrual cycle. In a study by Krassas and colleagues, 23.4 percent of 171 premenopausal women with hypothyroidism had irregular bleeding, compared with 8.4 percent in the control group, most often infrequent or very heavy bleeding. So three out of four had a regular cycle. More: The thyroid and female hormones.

Menopause: when two pictures overlap

A review by Uygur and colleagues describes how thyroid disorders become more common after menopause and how their complaints are often attributed to menopause. At the same time, high levothyroxine doses in older people can strain the heart and increase bone turnover. In this stage of life, too much is just as relevant as too little. More on this: Menopause: symptoms and phases.

Men: less often, but not unimportant

Men are affected less often. In a small study by Krassas and colleagues of 71 men with hyperthyroidism or hypothyroidism, 78.9 percent showed signs of erectile dysfunction on the questionnaire, compared with 33.8 percent in the control group. After treatment of the thyroid, questionnaire scores rose significantly in both hyperthyroidism and hypothyroidism. More: Prolactin and the thyroid in men.

Skin, tingling, eyes: what belongs to it and what needs checking

Skin. Dry skin is common but non-specific. In chronic hives without an identifiable trigger, most studies find thyroid antibodies in at least 10 percent, according to a systematic review by Kolkhir and colleagues; the reverse direction is only weakly supported. Vitiligo, the white skin patches, also occurs more often together with thyroid autoimmunity (see below).

Tingling. Tingling is not part of the core picture, but it has three neighbours that need checking. Carpal tunnel syndrome is associated with hypothyroidism, but only modestly after adjusting for confounders: in a meta-analysis by Shiri, the effect size fell from 2.15 to 1.44. In a study by Ness-Abramof and colleagues, 28 percent of 115 people with autoimmune thyroid disease had a low B12 level. And for unexplained nerve complaints, the British NICE guideline recommends considering a test for coeliac disease. New paralysis or numbness on one side of the body is an emergency: 112.

Eyes. Swollen eyelids and a puffy face can be part of hypothyroidism. That is something different from thyroid eye disease (endocrine orbitopathy), an inflammation of the tissue in the eye socket. It is typical of Graves' disease and rare in Hashimoto's.

In a university thyroid eye clinic, a team led by Kahaly found overt orbitopathy in 44 of 700 people with Hashimoto's, that is 6 percent, and 68.2 percent of these 44 had stimulating TSH receptor antibodies. Because it was a specialised clinic, the 6 percent probably overestimate the frequency in the general population. Eye complaints need assessment by an eye doctor and an endocrinologist; for the distinction, see Graves' disease and hyperthyroidism.

Mood

A meta-analysis by Siegmann and colleagues found depression (odds ratio 3.56) and anxiety disorders (odds ratio 2.32) more often in autoimmune thyroiditis, with highly heterogeneous studies and signs of publication bias. An association does not prove a cause. Depression is a distinct, serious illness and belongs in medical or psychotherapeutic treatment, regardless of the thyroid result. For that reason, ongoing antidepressant treatment is not changed on your own; stopping abruptly can carry its own risks. The crisis numbers are in the box above.

Another way to see it

Not all fatigue in Hashimoto's comes from the thyroid. That is not bad news but an invitation to keep looking: at iron, B12, sleep, mood and other illnesses. If the values are good and the complaints remain, read on in Normal values, still symptoms and Functional hypothyroidism.

And now you know why guidelines are cautious about symptoms: not out of lack of interest, but because the same complaints can have many causes.

Diagnosis: blood tests, ultrasound, which doctor, and why a home test is not enough

How does a suspicion become a diagnosis? The DEGAM guideline “Raised TSH in general practice” describes a clear sequence. Since 2023 it also includes pregnant women and women trying to conceive.

Stepwise diagnosis according to DEGAM

From a raised TSH to the question of Hashimoto's

1
TSH, read in relation to age

In general practice, values “should” count as raised as follows: from 18 to 70 years above 4.0 mU/l, over 70 to 80 years above 5.0, over 80 years above 6.0 mU/l. Laboratories sometimes use other cut-offs, which is why there is no universal table here.

2
Repeat

If a first value is above the age limit but no higher than 10.0 mU/l, with an unremarkable history, the measurement “should” first be repeated. TSH fluctuates.

3
Free T4 once

Then free T4 “should” be measured once. If it is within the reference range, this is called subclinical (latent) hypothyroidism; if it is below, overt hypothyroidism.

4
TPO antibodies once

“Only in latent hypothyroidism can TPO antibodies be determined once.” They “should” not be measured repeatedly or when TSH is in the normal range. A minority vote from the German Society of Endocrinology adds: with negative TPO antibodies, Tg antibodies can be tested once.

DEGAM S2k guideline, version 2.4, 2023 [Guideline]. The British NICE guideline NG145 recommends essentially the same: consider TPO antibodies with a raised TSH, but do not repeat them [Guideline].

According to DEGAM, TPO antibodies are raised in about 90 percent of people with Hashimoto's, Tg antibodies in about 70 percent. That also means: a negative result does not rule out Hashimoto's.

A group led by Rotondi compared 55 people with antibody-negative autoimmune thyroiditis with 110 people with classic Hashimoto's thyroiditis. The antibody-negative form ran a milder course; overt hypothyroidism was present in 5.4 versus 20.9 percent. So “antibody negative” does not automatically mean “healthy thyroid”.

Ultrasound: informative, but rarely decisive

On ultrasound, Hashimoto's often appears as hypoechoic, that is darker, tissue. In a study by Raber and colleagues of 451 people from a specialised clinic, the darkest pattern had a positive predictive value of 94 to 96 percent for autoimmune thyroiditis with hypothyroidism. An unremarkable pattern applied in 91 percent to people with normal function without TPO antibodies.

DEGAM nevertheless recommends not performing routine ultrasound with a raised TSH (“should not”), because the finding is not relevant to the treatment decision. Both are true side by side: ultrasound can support the diagnosis and should be used selectively, for example with nodules (Thyroid nodules). What free T3 and reverse T3 contribute is covered in Thyroid values that count and Reverse T3.

An interfering factor many people do not know about: biotin

A team led by Li gave six healthy people 10 mg of biotin daily for seven days (study data). Interference occurred in 9 of 23 laboratory assays that use biotin, falsely high or falsely low depending on the test principle. Biotin is found in many hair and nail supplements. Mention that you take it to your practice before a blood draw.

Which doctor?

A general practice is well placed for the initial work-up and follow-up. According to DEGAM, referral to endocrinology “should” take place when TSH and free T4 are raised at the same time, and the guideline additionally names a TSH that does not fall despite a full dose and confirmed intake. Clinically sensible, even if not regulated there, is co-management by a specialist with nodules, eye involvement and pregnancy. Fertility treatment belongs in a reproductive medicine setting.

Why there is no reliable home test

Home tests often measure the same values as your practice. The difficulty rarely lies in the measurement, but in the interpretation.

  • Roughly one in nine people has positive antibodies; on their own they are no reason for treatment.
  • Antibody-negative forms exist, so a negative result offers only limited reassurance.
  • TSH fluctuates, and biotin can distort results.
  • According to DEGAM, complaints alone do not confirm the diagnosis.

For this article I did not find a study that tested commercial home test kits for this question.

Another way to see it

A Hashimoto's diagnosis is not a single value but a puzzle made of function, antibodies, ultrasound and course. A home test can be a reason for a conversation; it is not a diagnosis.

And now you know why the same number can mean different things in two reports.

Course: from antibodies to hypothyroidism, and what a “flare” is

After the diagnosis, many people first ask: when will I need tablets? The honest answer is a probability, not a date.

Stage 1
Antibodies, normal function

TSH and free T4 within the reference range, TPO antibodies positive.

Stage 2
Subclinical hypothyroidism

TSH raised, free T4 still within the reference range.

Stage 3
Overt hypothyroidism

TSH raised, free T4 below the reference range.

Not everyone passes through all stages, and many stay on one for a long time. How likely the next step is, two cohorts show.

Cohort, 20 years, n=2,779 The Whickham study

A team led by Vanderpump followed a random sample of 2,779 adults for 20 years, matched to the British population by age, sex and social class.

New spontaneous hypothyroidism occurred in women at 3.5 per 1,000 survivors per year, in men at 0.6. Positive antibodies and a raised TSH clearly increased the likelihood, most strongly together (table). Even a TSH above 2 mU/l increased it, amplified by antibodies. A positive family history, on the other hand, was not associated with a higher risk.

For you this means: antibodies can shift the likelihood over decades; they are not a verdict. Odds ratios are not percentage risks, and the higher numbers in men mainly reflect their low baseline risk.

Vanderpump MP, Tunbridge WM, French JM, et al. Clin Endocrinol (Oxf). 1995;43(1):55-68. PMID: 7641412 · DOI: 10.1111/j.1365-2265.1995.tb01894.x [Cohort, n=2,779]
Finding at the first examinationWomenMen
raised TSH only8 (3 to 20)44 (19 to 104)
positive antibodies only8 (5 to 15)25 (10 to 63)
raised TSH and positive antibodies38 (22 to 65)173 (81 to 370)
Odds ratios (95 percent confidence interval) for later hypothyroidism after 20 years, not percentage risks.
Cohort, prospective, n=82 The TSH level tells you a lot

A group led by Huber followed 82 women with subclinical hypothyroidism for a mean of 9.2 years with annual check-ups.

After 10 years, 0 percent with a baseline TSH of 4 to 6 mU/l had developed overt hypothyroidism, 42.8 percent with above 6 to 12 mU/l, and 76.9 percent with above 12 mU/l. With positive antibodies it was 58.5 percent, without 23.2 percent. A large proportion remained subclinical after 10 years.

For you this means: not everyone will need tablets sooner or later. TSH level and antibody status together can give good orientation on how closely monitoring should take place.

Huber G, Staub JJ, Meier C, et al. J Clin Endocrinol Metab. 2002;87(7):3221-6. PMID: 12107228 · DOI: 10.1210/jcem.87.7.8678 [Cohort, prospective, n=82]
Another way to see it

Hashimoto's is not a countdown. It is a probability that you know about and can keep an eye on. That is exactly why check-ups make sense: not out of fear, but so that hypothyroidism does not go unnoticed for years.

Hashitoxicosis: when Hashimoto's briefly looks like an overactive thyroid

When immune cells destroy thyroid tissue, stored hormones can enter the bloodstream. A temporary overactive phase can then develop, even though in the long term the condition is more likely to lead into hypothyroidism.

How long this can last is shown by an analysis by Nabhan and colleagues: of 69 children with autoimmune thyroiditis, 8 had hashitoxicosis, and the overactive phase lasted 31 to 168 days. Afterwards, 3 children became hypothyroid and 5 had normal function, and the picture partly overlapped with Graves' disease. Such a phase needs to be distinguished from Graves' disease by a doctor, and data from children cannot simply be transferred to adults.

What a “flare” means and what it does not

“Hashimoto's flare” is an everyday word, not a defined term in endocrinology, and I have not found a study that measures it. The experience is still real. Several things can lie behind it:

  • a temporary overactive phase, as hashitoxicosis, silent or postpartum thyroiditis,
  • progressing hypothyroidism, in which the previous dose is no longer enough,
  • a change in how the medication is absorbed, for example due to new calcium, iron or acid blocker products,
  • a pregnancy, which raises hormone requirements early on,
  • or something outside the thyroid: iron deficiency, B12 deficiency, an infection, a depressive episode.

According to DEGAM, a rise in antibodies has no consequence for treatment. Stress as a trigger has been studied more for Graves' disease; for Hashimoto's there are only a few reports, according to a review by Mizokami and colleagues. Fever with a painful thyroid fits better with another form of thyroiditis and needs prompt assessment.

What I observe clinically

Many people know the pattern of a “flare” coinciding with a new habit: a new supplement in the morning, a stomach protector, coffee straight after the tablet. That is a clinical observation, not a study finding, and a reason to have the values checked first when new complaints appear, rather than adjusting the dose yourself.

And now you know why a “flare” is not a diagnosis, but a question that deserves an answer.

Treatment: when levothyroxine according to guidelines, and how to take it well

Hardly any sentence comes as quickly after the diagnosis as this one: this is for life now. For many people with overt hypothyroidism it applies; for an antibody result alone it does not.

In Hashimoto's, what is treated is not the antibody but the hormone deficiency. The treatment of choice is levothyroxine, that is synthetic T4.

Guidelines side by side

When levothyroxine is recommended

DEGAM S2k, 2023 · general practice · adults
Overt hypothyroidism: replacement “should” always be given. Subclinical hypothyroidism: individual decision; without complaints and with TSH up to 10 mU/l, replacement “should” not be given, regardless of age. Up to age 75, therapy “should” be started with TSH above 10 mU/l; forgoing treatment under monitoring up to a TSH below 20 mU/l is an alternative after informed discussion. Over age 75, treatment “can” be forgone up to a TSH below 20 mU/l. Levothyroxine monotherapy “should” be the treatment of choice. The starting dose “should” be set individually with a TSH target corridor of 0.4 to 4.0 mU/l.
ETA 2013 · European specialist society · subclinical hypothyroidism
Under 65 to 70 years with TSH above 10 mU/l, treatment is recommended even without complaints. With TSH below 10 mU/l and matching complaints, a trial of therapy should be considered and reviewed 3 to 4 months after TSH is within the reference range, and usually stopped if there is no improvement. Target for most adults (“should”): a stable TSH in the lower half of the reference range, 0.4 to 2.5 mU/l.
NICE NG145 · British guideline
Consider levothyroxine with TSH of 10 mU/l or higher on two measurements 3 months apart. Under 65 years with TSH above the reference range but below 10 mU/l, and complaints: consider a 6-month trial. Keep TSH within the reference range without suppressing it.

[Guideline] DEGAM with the recommendation strength as worded in the German original (“soll” = shall, “sollte” = should, “kann” = can), translated here; ETA and NICE paraphrased from the English originals.

Why 0.4 to 4.0 at DEGAM and 0.4 to 2.5 at ETA? DEGAM writes for general practice and aims to avoid overtreatment, because complaints are non-specific and studies in the grey zone have not shown benefit. ETA orients itself to the lower half of the reference range. I have not found a randomised trial showing a patient-relevant advantage of either target outside pregnancy. Which target suits you belongs in a conversation with your doctor.

Cohort, retrospective, n=162,369 Too much and too little

A team led by Thayakaran analysed British general practice data from 162,369 people with newly diagnosed hypothyroidism and 863,072 TSH measurements.

Mortality was raised with TSH below 0.1 mIU/l (hazard ratio 1.18), as well as at 4 to 10 (1.29) and above 10 mIU/l (2.21). Within the recommended range there were no clinically meaningful differences.

For you this means: more hormone is not automatically better. Observational data do not prove a cause, but they are a good reason not to change the dose based on how you feel.

Thayakaran R, Adderley NJ, Sainsbury C, et al. BMJ. 2019;366:l4892. PMID: 31481394 · DOI: 10.1136/bmj.l4892 [Cohort, retrospective, n=162,369]

And T3 or natural thyroid extracts? DEGAM recommends not prescribing them (“should not”), and NICE recommends not offering thyroid extract. The American guideline from 2014 keeps levothyroxine as the standard, found no consistently strong evidence that combinations or extracts are superior, and names the need for better measures than TSH alone. According to the Lancet seminar, around 10 percent of those treated have persistent complaints despite lab values in the target range. More in Symptoms despite levothyroxine, Natural thyroid hormones and From T4 to T3.

Taking it: an underestimated part of treatment

Levothyroxine is sensitive: how much reaches the blood can depend on what is in the stomach at the same time. DEGAM names as practical taking it on an empty stomach, for example at least 30 minutes before a meal and before other medicines, spaced apart from supplements. It describes taking it in the evening before bed as a suitable alternative.

RCT, crossover, n=105 Morning or evening?

A team led by Bolk had 105 people on levothyroxine take it in the morning and in the evening, double-blind and in random order; 90 were analysed.

With evening intake, TSH was 1.25 mIU/l lower and free T4 0.07 ng/dl higher. There were no differences in quality of life.

For you this means: evening is an evidence-based alternative. Because the values can shift, a switch should be agreed with your doctor and checked afterwards.

Bolk N, Visser TJ, Nijman J, et al. Arch Intern Med. 2010;170(22):1996-2003. PMID: 21149757 · DOI: 10.1001/archinternmed.2010.436 [RCT, crossover, n=105]
Coffee

In absorption tests by Benvenga and colleagues, coffee taken with the tablet lowered the amount absorbed by 36 percent in patients and 27 percent in volunteers; coffee one hour later did not. Small numbers.

Calcium

In a study by Singh and colleagues, 20 people took 1,200 mg of calcium as carbonate with levothyroxine for three months (study data). TSH rose from 1.6 to 2.7 mIU/l and was 1.4 after the calcium phase ended.

Iron

In a study by Campbell and colleagues, 14 people took 300 mg of ferrous sulphate with thyroxine for 12 weeks (study data), and TSH rose from 1.6 to 5.4 mU/l.

Lab In the test tube, the two formed a poorly soluble complex.

Stomach acid

In a study by Centanni and colleagues, thyroxine requirements were 22 to 34 percent higher with Helicobacter or atrophic gastritis, and on omeprazole TSH rose in all 10 people treated. The participants had nodular goitre and a lower TSH target.

A systematic review by Wiesner and colleagues covering 63 studies summarises: morning and bedtime are equivalent; for coffee, soy, fibre, calcium and iron the evidence is limited but in each case points to reduced absorption.

If you want to change anything about the time you take it, accompanying medicines or the preparation, discuss it beforehand, because TSH can shift as a result. A new acid blocker, calcium or iron product is also a good reason for a check-up. More: Acid blockers and iron absorption.

Another way to see it

If TSH fluctuates while on tablets, it is not always down to the thyroid. Sometimes it is worth looking at your morning first: coffee, muesli, calcium, iron, stomach protection. The tablet is small; its surroundings count too.

And now you know why the same dose can produce different values in two people.

Check-ups: how often, which values, and when ultrasound

TSH once a year, and that is it? For stable situations that is a reasonable rhythm according to guidelines, but not for everyone and not from the start.

Monitoring intervals according to guidelines

  • After starting or changing the dose of levothyroxine: no earlier than 8 weeks, then every six months, and finally once a year (DEGAM). NICE: consider measurements every 3 months until two similar values within the reference range are available, then once a year.
  • After a very high baseline TSH: it can take up to 6 months for TSH to reach the reference range (NICE).
  • Subclinical hypothyroidism without treatment: TSH “can” be checked again after 6 to 12 months, or at a longer interval after informed discussion (DEGAM).
  • Pregnancy on replacement: TSH at least once per trimester and 6 weeks after birth (DEGAM).
  • Antibodies: no repeat measurement, because the course has no consequence for treatment (DEGAM “should not”, NICE likewise).

[Guideline] DEGAM S2k 2023 and NICE NG145.

And with positive antibodies and a normal TSH? None of the guidelines I read names a fixed interval here, and DEGAM even advises against measuring antibodies when TSH is normal. If the result already exists, Whickham and Huber support keeping an eye on TSH at longer intervals, especially if it is above 2 mU/l or if you are trying to conceive. That is my clinical assessment, not a guideline recommendation.

How antibodies may be lowered is discussed in Lowering Hashimoto's antibodies. According to guidelines, the titre is not the measure used for treatment.

If complaints persist on therapy, DEGAM says alternative causes “should” be checked, such as other endocrine or autoimmune diseases and deficiency states. This can include ferritin, B12, vitamin D and coeliac serology. Reference ranges depend on the laboratory, which is why there is no table here.

When ultrasound makes sense again

The diagnosis alone does not call for routine ultrasound. The reason would be new findings: a palpable nodule, enlargement, a feeling of pressure, hoarseness or difficulty swallowing.

Lymphoma and thyroid cancer: a sober assessment

Many people ask this question quietly. It deserves a clear answer with numbers.

Cohort, n=829 Relative and absolute risk

A team led by Holm followed 829 people with cytologically confirmed chronic lymphocytic thyroiditis and 829 comparison persons with colloid goitre through the Swedish cancer registry.

The total number of tumours was not raised: 53 observed versus 52.7 expected. Malignant thyroid lymphoma occurred in 4 of the 829 people, where 0.06 had been expected. That corresponds to a relative risk of 67.

For you this means: the relative risk sounds dramatic, but in absolute terms 4 of 829 is less than half a percent over many years. A rapidly growing nodule needs prompt assessment, without fear having to dominate everyday life.

Holm LE, Blomgren H, Löwhagen T. N Engl J Med. 1985;312(10):601-4. PMID: 3838363 · DOI: 10.1056/NEJM198503073121001 [Cohort, n=829]

For thyroid cancer, a meta-analysis by Resende de Paiva and colleagues covering 36 studies and 64,628 people found a relative risk of 1.40 for papillary carcinoma, 9.74 for thyroid lymphoma, and no association for other carcinomas. A relative risk of 1.40 means: a rare event becomes a little less rare. The abstract does not give absolute numbers. On nodules: Thyroid nodules.

For scale in the general population: according to the German Centre for Cancer Registry Data, 4,193 women and 1,797 men in Germany were newly diagnosed with thyroid cancer in 2022, age-standardised 8.9 and 3.6 per 100,000. The relative 5-year survival rate was 94 and 88 percent. These figures do not apply specifically to Hashimoto's and cannot be combined with the relative risk.

Another way to see it

Check-ups are not a vote of no confidence in your body. They are the calm alternative to both overlooking things and constantly measuring.

And now you know which check-ups follow the guidelines and where my clinical assessment begins.

Trying to conceive, pregnancy and the time after

Wanting a child changes how you look at a lab value. Suddenly TSH is no longer just your number, and a clear plan counts for more than any search engine.

Pregnancy is its own care setting with its own target values. What applies to you belongs in medical care, and no dose is adjusted on your own.

Three guidelines, three settings

TSH before and during pregnancy

DEGAM S2k, 2023 · general practice · including pregnancy and trying to conceive, not fertility treatment
Upper TSH reference value for pregnant women: 4.0 mU/l, unless regional values are available. Routine TSH screening when trying to conceive or in pregnancy without known disease “should” not take place. With overt hypothyroidism in pregnancy, replacement “shall” be given. In pregnant women already on treatment, replacement “shall” be continued, aiming for a TSH between 0.4 and 4.0 mU/l. After birth, the dose “should” be reduced to the pre-pregnancy dose, as a medical decision, not on your own. According to the background text, about 70 to 80 percent of those already on treatment temporarily need about 20 to 30 percent more.
ETA 2021 · European specialist society · before and during assisted reproduction
Women with treated hypothyroidism should (“should” in the original) have a TSH below 2.5 mIU/l before fertility treatment. Women in subfertile couples should be routinely screened for thyroid disorders.
ATA 2026 · American specialist society · preconception, pregnancy, postpartum period
The most recent guideline, also covering women with infertility, developed using GRADE with representatives of ten international specialist societies. The authors emphasise that much of the evidence is of low to moderate quality. I was not able to check its individual recommendations in full text and therefore do not reproduce them verbatim.

[Guideline] DEGAM as worded in the German original, translated here; ETA paraphrased from the English original. The ATA guideline from 2017 has been superseded by the 2026 version.

The numbers seem to contradict each other, but they apply to different settings, and I deliberately leave the difference standing here. Which target fits depends on whether a natural pregnancy or fertility treatment is planned and on your history.

For T3 and thyroid extracts, the DEGAM recommendation not to prescribe them (“should not”) already applies outside pregnancy. If you take such preparations and are planning a pregnancy, raise it early with the practice looking after you, before planning becomes concrete. Any switch belongs in medical hands.

RCT, n=952 Levothyroxine as a precaution with normal function?

The TABLET trial by Dhillon-Smith and colleagues randomised 952 women with TPO antibodies, normal thyroid function and a history of miscarriage or infertility. Starting before conception, they received 50 µg of levothyroxine daily or placebo (study data).

The live birth rate was 37.4 percent (176 of 470) in the levothyroxine group and 37.9 percent (178 of 470) in the placebo group, relative risk 0.97. There were also no differences in miscarriage and preterm birth.

For you this means: in this trial, positive antibodies with normal function were no reason for precautionary levothyroxine, and DEGAM takes the same view. In assisted reproduction, a different decision may be made in the specialist setting.

Dhillon-Smith RK, Middleton LJ, Sunner KK, et al. N Engl J Med. 2019;380(14):1316-1325. PMID: 30907987 · DOI: 10.1056/NEJMoa1812537 [RCT, n=952]

After birth

After giving birth, postpartum thyroiditis can appear, a variant within the Hashimoto's spectrum. For women already on treatment, DEGAM provides for a TSH check 6 weeks after birth. But exhaustion after birth has many causes, including iron deficiency (Iron deficiency in pregnancy). According to DEGAM, no recommendation can be derived for selenium in pregnancy. On the iodine question: Iodine and the thyroid.

Another way to see it

A TSH target is not an exam you have to pass. It is a tool that is set for a particular stage of life. If two practices name different numbers, it may be that both are following their guideline.

And now you know why the same number is read differently before fertility treatment than in general practice.

Associated autoimmune diseases, heredity, and when a test can make sense

Once the immune system has targeted one organ, the question is obvious: will there be more? Sometimes yes, mostly no.

Cross-sectional, n=3,286 How often something else comes along

A team led by Boelaert surveyed 3,286 people from British thyroid clinics, including 495 with Hashimoto's, about further autoimmune diseases.

14.3 percent of people with Hashimoto's had another autoimmune disease, most often rheumatoid arthritis at 4.24 percent. The abstract reports relative risks above 10 for Graves' disease and Hashimoto's combined, for pernicious anaemia, systemic lupus, Addison's disease, coeliac disease and vitiligo.

For you this means: about one in seven people in this clinic sample had a second autoimmune disease, by self-report. The authors advise keeping this in mind with new or non-specific complaints.

Boelaert K, Newby PR, Simmonds MJ, et al. Am J Med. 2010;123(2):183.e1-9. PMID: 20103030 · DOI: 10.1016/j.amjmed.2009.06.030 [Cross-sectional, multicentre, n=3,286]
Coeliac disease

In a meta-analysis by Roy and colleagues of 6,024 people with autoimmune thyroid disease, coeliac disease was confirmed by biopsy in 1.6 percent, in children in 6.2, in adults in 2.7 percent. NICE recommends offering a blood test at the time of diagnosis in autoimmune thyroid disease. The test is only meaningful on a gluten-containing diet, so do not go gluten-free beforehand. More: Recognising coeliac disease.

Type 1 diabetes

Here the direction runs the other way. In a meta-analysis by Nederstigt and colleagues of 293,889 people with type 1 diabetes, 9.8 percent had hypothyroidism. NICE therefore recommends offering thyroid tests to people with type 1 diabetes or other autoimmune diseases.

Stomach, B12, iron

According to a review by Cellini and colleagues, 10 to 40 percent of people with Hashimoto's have gastric disorders. The consequence can be iron deficiency, later B12 deficiency up to pernicious anaemia, plus poorer absorption of levothyroxine. More: Measuring B12 deficiency correctly.

Vitiligo

In vitiligo, autoimmune thyroid disease was present in 14.3 percent in the meta-analysis by Vrijman and colleagues, relative risk 2.5. The authors consider a screening recommendation possible only after better studies.

With a raised TSH, DEGAM names these factors, among others, that make hypothyroidism more likely: autoimmune thyroid disease or hypothyroidism in first-degree relatives, your own autoimmune diseases such as type 1 diabetes, Addison's disease, coeliac disease, vitiligo and pernicious anaemia, as well as depression.

What follows from this

What can make sense is coeliac serology at diagnosis, a look at B12 and ferritin with matching complaints, and attention to anything new that comes along.

Is Hashimoto's hereditary?

Twin study, 2,945 pairs Genes count, but they do not decide alone

A team led by Brix examined 2,945 female Danish twin pairs for autoimmune hypothyroidism.

Concordance was 0.55 in identical pairs and 0.0 in non-identical pairs. Of the 15 healthy twin sisters of affected women, 8 had thyroid antibodies.

For you this means: genes appear to play a large role. But because even identical twins are not always both affected, the environment counts too.

Brix TH, Kyvik KO, Hegedüs L. J Clin Endocrinol Metab. 2000;85(2):536-9. PMID: 10690851 · DOI: 10.1210/jcem.85.2.6385 [Twin study, 2,945 pairs]

A study of healthy Danish twins by Hansen and colleagues estimated the genetic share in the tendency to form thyroid antibodies at 73 percent. That does not mean Hashimoto's with hypothyroidism is 73 percent hereditary, and in Whickham family history was not associated with later hypothyroidism. A predisposition, yes; destiny, no. DEGAM does not recommend general TSH screening of adults without complaints (“should not”). With complaints or when trying to conceive, however, family history belongs in the conversation with your doctor. Which genes are involved: Hashimoto's and the immune system.

And now you know why a second look can make sense without testing everything straight away.

Selenium, vitamin D, iron, gluten and stress: what may add to the picture, and with what level of evidence

This is the part many people look for first. Honesty matters most here, because expectations are often bigger than the data.

The opposing view first

What the general practice guideline says

“There is no evidence that the (additional) administration of trace elements, herbal preparations or dietary supplements (e.g. iodine, selenium, vitamins) has a patient-relevant benefit in hypothyroidism and Hashimoto's thyroiditis.” DEGAM S2k, 2023, translated from German [Guideline]

This applies to endpoints such as well-being and course. Lab values are a different level, and this section is structured with that separation in mind.

Selenium

Supported by meta-analyses, for lab values: A meta-analysis of randomised trials by Huwiler and colleagues covering 35 studies found, with selenium in people not on hormone therapy, a lower TSH (standardised mean difference minus 0.21) and, in people with and without hormone therapy, lower TPO antibodies (minus 0.96, with high heterogeneity), without noticeably more side effects, with moderate certainty of evidence. A Cochrane review by van Zuuren and colleagues had found only four studies with 463 people in 2013 and called the evidence incomplete.

RCT, n=412 Titre versus well-being

The CATALYST trial by Larsen and colleagues gave 412 adults with TPO antibodies on levothyroxine 200 µg of selenium or placebo for twelve months (study data) and measured thyroid-related quality of life.

Quality of life improved in both groups with no difference (total score 28.8 on selenium, 28.0 on placebo, P = 0.602). TPO antibodies were lower on selenium (1,995 versus 2,344 kIU/l, P = 0.016), with no effect on the levothyroxine dose.

For you this means: the titre may fall, but in this large trial well-being was not measurably different from placebo.

Larsen C, Winther KH, Cramon PK, et al. Eur Thyroid J. 2024;13(1):e230175. PMID: 38215286 · DOI: 10.1530/ETJ-23-0175 [RCT, n=412]

Safety: Depending on the dose, selenium is not harmless. In 2023 EFSA set a tolerable upper intake level of 255 µg per day for adults, including pregnant and breastfeeding women, exceeded mainly with high-dose supplements or regular consumption of Brazil nuts. In a secondary analysis of the NPC trial by Stranges and colleagues, more people developed type 2 diabetes on 200 µg of selenium daily (study data) over a mean of 7.7 years than on placebo, hazard ratio 1.55. More: Selenium, zinc, iron and vitamin D and Minerals in balance.

Vitamin D

Supported by a large RCT, but not for Hashimoto's alone: In the VITAL trial by Hahn and colleagues, 25,871 older adults received 2,000 IU of vitamin D daily or placebo for a median of 5.3 years (study data). Autoimmune diseases overall occurred less often (hazard ratio 0.78); autoimmune thyroid disease was only one part of this composite endpoint.

Meta-analysis with a caveat: A meta-analysis by Tang and colleagues of 12 RCTs with 862 people found lower TPO antibodies, but included studies with calcitriol, the active hormone form of vitamin D, which is used as a medicine and performed more strongly than vitamin D2 or D3.

Assessment from a review: Hu and Rayman consider a low vitamin D status more likely to be a consequence of the autoimmune process and advise checking the status and correcting a deficiency. Too much vitamin D can raise calcium levels dangerously: Vitamin D overdose.

Iron and ferritin

Mechanistically plausible, human data from cross-sectional studies: Thyroid peroxidase, the enzyme that builds thyroid hormones, contains iron. According to Hu and Rayman, people with Hashimoto's often have iron deficiency, partly because of accompanying autoimmune gastritis. A meta-analysis by Garofalo and colleagues of 10 cross-sectional studies found lower free T4 values with iron deficiency (minus 1.18 pmol/l) and more frequent positive antibodies, with extremely high heterogeneity. Cause and consequence cannot be separated from this.

Iron and levothyroxine should be taken at separate times. I do not derive a universal ferritin target table from these data. In my clinical observation, a ferritin at the lower end of the reference range is often read too quickly as unremarkable in Hashimoto's. Why is explained in Ferritin: what is normal and Iron deficiency and the thyroid as sleep thieves.

Gluten

Supported only in coeliac disease: Without coeliac disease, a meta-analysis by Piticchio and colleagues of four studies with 87 people found a lower TSH on a gluten-free diet, but no significant decrease in TPO antibodies (p = 0.07) or Tg antibodies (p = 0.06). The authors do not consider the data sufficient for a general recommendation. A newer meta-analysis by Araújo and colleagues of three RCTs with 110 people even found increased TPO antibodies alongside decreased Tg antibodies, with very uncertain evidence.

If you would like to eat gluten-free, it is best to have coeliac disease ruled out beforehand, because the test is no longer meaningful afterwards. More in Nutrition in Hashimoto's, Gluten without coeliac disease and Fasting with Hashimoto's.

Stress, environment and iodine

Mechanistically plausible, human data thin: According to the review by Mizokami and colleagues, stress may be an environmental factor for thyroid autoimmunity, but the evidence is mostly indirect. That is no reason to feel guilty if the diagnosis came during a stressful time; it is an invitation to pay attention to the stress axis (Cortisol and the HPA axis). There are separate articles on heavy metals and Hashimoto's, on iodine and on the anthroposophic view of the thyroid.

Another way to see it

Selenium, vitamin D and the like are not an alternative to levothyroxine when hypothyroidism is present. Where a deficiency exists, they can be a complement. The order is: measure first, then correct, then check honestly whether anything changes.

And now you know why, with supplements, I would rather measure first than promise something.

Three things to take away
  1. Read your result in three parts: antibodies, TSH, free T4.
  2. Talk about how you take it: timing, coffee, calcium, iron, acid blockers, biotin.
  3. Ask for the second look: coeliac test at diagnosis, iron, B12 and vitamin D with complaints, a plan before trying to conceive.

This is not about one lab value. It is about being able to feel at home in your body again.

Frequently asked questions about Hashimoto's

What exactly is Hashimoto's?

Hashimoto's is a chronic autoimmune inflammation of the thyroid, medically called chronic lymphocytic autoimmune thyroiditis. In regions with adequate iodine supply it is the most common cause of hypothyroidism. Not everyone with thyroid antibodies, however, develops hypothyroidism that needs treatment.

How common is Hashimoto's?

That depends on what is being counted. In the US survey NHANES III, 11.3 percent of people aged 12 and over had positive TPO antibodies, and 0.3 percent had overt hypothyroidism. A meta-analysis of 48 studies arrives at 7.5 percent Hashimoto's in adults, with women affected about four times as often. These figures cannot be combined into one number.

What are the symptoms of Hashimoto's in women?

The complaints are non-specific: fatigue, lack of drive, sensitivity to cold, weight gain. Hypothyroidism can show up in the menstrual cycle: in one study, 23.4 percent of women with hypothyroidism had irregular bleeding, compared with 8.4 percent in the control group. In menopause the pictures overlap, and too much hormone then becomes just as relevant as too little.

What are the symptoms of Hashimoto's in men?

Men are affected less often and have similar, non-specific complaints. In a small study of 71 men with hyperthyroidism or hypothyroidism, 78.9 percent showed signs of erectile dysfunction, compared with 33.8 percent in the control group. After treatment of the thyroid, questionnaire scores rose significantly. The study is not limited to Hashimoto's.

Can Hashimoto's cause tingling, skin problems or eye complaints?

Tingling is not part of the core picture; carpal tunnel syndrome, B12 deficiency and, with unexplained nerve complaints, coeliac disease should be checked. Chronic hives and vitiligo occur more often together with thyroid autoimmunity. Eye involvement is rare in Hashimoto's, and double vision or worsening sight need to be seen by an eye doctor right away.

Which blood tests are needed for the diagnosis?

According to the German general practice guideline from DEGAM, TSH comes first, read in relation to age. A mildly raised value should be repeated and free T4 measured once. Only in subclinical hypothyroidism may TPO antibodies be tested once, and if negative, according to a minority vote, Tg antibodies once. Ultrasound should not be done routinely.

Which doctor makes the diagnosis?

A general practice is well placed for the work-up and follow-up. According to DEGAM, referral to endocrinology should take place when TSH and free T4 are raised at the same time; the guideline also names a TSH that does not fall despite a full dose. With nodules, eye involvement and pregnancy, co-management by a specialist makes clinical sense.

Is there a reliable Hashimoto's home test?

Not in the sense of a diagnosis. Home tests often measure the same values as a practice, but interpreting them is difficult. Roughly one in nine people has positive antibodies, and on their own they are no reason for treatment. There are antibody-negative forms, TSH fluctuates, and biotin can distort results. A home test can be a reason for a conversation; it is not a diagnosis.

What is a Hashimoto's flare?

“Flare” is not a defined medical term, and I have not found a study that measures it. Behind it may lie a temporary overactive phase such as hashitoxicosis, progressing hypothyroidism, a change in how the medication is absorbed, a pregnancy or causes outside the thyroid. New complaints need medical assessment, and the dose is not changed on your own.

Do I have to take levothyroxine if I have Hashimoto's?

Not automatically; what is treated is the hormone deficiency, not the antibody. According to DEGAM, overt hypothyroidism should always be treated with replacement. In subclinical hypothyroidism without symptoms and with TSH up to 10 mU/l, replacement should not be given; up to age 75 with TSH above 10 mU/l, therapy should be started. The ETA guideline from 2013 recommends considering a monitored trial of therapy in younger people with TSH below 10 mU/l and matching symptoms.

How do I take levothyroxine correctly, for example with coffee?

According to DEGAM, a practical approach is taking it on an empty stomach, for example at least 30 minutes before a meal, spaced apart from supplements and other medicines; in the evening before bed is an alternative. Coffee right with the tablet, calcium, iron and acid blockers can reduce absorption. Any change is best discussed beforehand.

How often should the values be checked?

After starting or changing the dose, no earlier than 8 weeks, then every six months, and finally once a year (DEGAM). In untreated subclinical hypothyroidism, TSH can be checked after 6 to 12 months; in pregnancy on replacement, at least once per trimester. Antibodies are not measured repeatedly, and ultrasound only with new findings.

Which TSH value applies when trying to conceive and in pregnancy?

That depends on the setting. The German general practice guideline from DEGAM names a TSH between 0.4 and 4.0 mU/l for pregnant women already on treatment. The European ETA guideline from 2021 recommends a TSH below 2.5 mIU/l on levothyroxine before fertility treatment. Which target fits belongs in medical care.

Is Hashimoto's hereditary, and can selenium, vitamin D or a gluten-free diet make a difference?

A predisposition, yes: in identical twins the concordance was 0.55, in non-identical twins 0.0, so the environment counts too. In studies, selenium was able to lower antibodies, but in the CATALYST trial quality of life was no better than with placebo. A review recommends checking and correcting vitamin D deficiency; the Hashimoto's studies on this mainly measure lab values. A gluten-free diet is only supported by evidence in coeliac disease.

Where to go next in the Thyroid Guide

This overview is the map; the details are here:

All other articles in the Thyroid Guide:

SJ

Shukri Jarmoukli

Physician, Integrative Medicine · ViveCura Berlin

I work at the interface of conventional medicine, functional medicine and Clinical Psychoneuroimmunology (KPNI). With Hashimoto's, I am interested in both: careful dose adjustment according to guidelines and the questions alongside it, from iron and B12 to how you take your tablet in the morning.

This article does not replace medical advice and is expressly not a guide to changing an existing treatment. It is meant to give you the right questions for your next appointment.

ViveCura, Privatpraxis Shukri Jarmoukli, Skalitzer Straße 137, 10999 Berlin

Scientific sources

  1. German College of General Practitioners and Family Physicians (Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin, DEGAM). Erhöhter TSH-Wert in der Hausarztpraxis (Raised TSH in general practice). S2k guideline, AWMF register no. 053-046, version 2.4, revised 04/2023, valid until 05/2027. register.awmf.org [Guideline]
  2. National Institute for Health and Care Excellence. Thyroid disease: assessment and management. NICE guideline NG145, 2019, last updated 12 October 2023. nice.org.uk [Guideline]
  3. National Institute for Health and Care Excellence. Coeliac disease: recognition, assessment and management. NICE guideline NG20, 2015. nice.org.uk [Guideline]
  4. Pearce SH, Brabant G, Duntas LH, et al. 2013 ETA Guideline: Management of Subclinical Hypothyroidism. Eur Thyroid J. 2013 Dec;2(4):215-28. PMID: 24783053 · DOI: 10.1159/000356507 [Guideline]
  5. Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid. 2014 Dec;24(12):1670-751. PMID: 25266247 · DOI: 10.1089/thy.2014.0028 [Guideline]
  6. Poppe K, Bisschop P, Fugazzola L, et al. 2021 European Thyroid Association Guideline on Thyroid Disorders prior to and during Assisted Reproduction. Eur Thyroid J. 2021 Feb;9(6):281-295. PMID: 33718252 · DOI: 10.1159/000512790 [Guideline]
  7. Korevaar TIM, Leung AM, Alexander EK, et al. American Thyroid Association 2026 Guidelines for Thyroid Disease in Preconception, Pregnancy, and Postpartum. Thyroid. 2026 May;36(5):481-544. PMID: 42219800 · DOI: 10.1177/10507256261445624 [Guideline]
  8. EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Turck D, Bohn T, et al. Scientific opinion on the tolerable upper intake level for selenium. EFSA J. 2023 Jan;21(1):e07704. PMID: 36698500 · DOI: 10.2903/j.efsa.2023.7704 [Official document]
  9. Taylor PN, Medici MM, Hubalewska-Dydejczyk A, Boelaert K. Hypothyroidism. Lancet. 2024 Oct;404(10460):1347-1364. PMID: 39368843 · DOI: 10.1016/S0140-6736(24)01614-3 [Review]
  10. Caturegli P, De Remigis A, Rose NR. Hashimoto thyroiditis: clinical and diagnostic criteria. Autoimmun Rev. 2014;13(4-5):391-7. PMID: 24434360 · DOI: 10.1016/j.autrev.2014.01.007 [Review]
  11. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002 Feb;87(2):489-99. PMID: 11836274 · DOI: 10.1210/jcem.87.2.8182 [Cross-sectional, n=17,353]
  12. Hu X, Chen Y, Shen Y, et al. Global prevalence and epidemiological trends of Hashimoto's thyroiditis in adults: A systematic review and meta-analysis. Front Public Health. 2022;10:1020709. PMID: 36311599 · DOI: 10.3389/fpubh.2022.1020709 [Meta-analysis, k=48]
  13. Carlé A, Karmisholt JS, Knudsen N, et al. Does Subclinical Hypothyroidism Add Any Symptoms? Evidence from a Danish Population-Based Study. Am J Med. 2021 Sep;134(9):1115-1126.e1. PMID: 33872585 · DOI: 10.1016/j.amjmed.2021.03.009 [Cross-sectional, n=7,995]
  14. Stott DJ, Rodondi N, Kearney PM, et al. Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism. N Engl J Med. 2017 Jun;376(26):2534-2544. PMID: 28402245 · DOI: 10.1056/NEJMoa1603825 [RCT, n=737]
  15. Krassas GE, Pontikides N, Kaltsas T, et al. Disturbances of menstruation in hypothyroidism. Clin Endocrinol (Oxf). 1999 May;50(5):655-9. PMID: 10468932 · DOI: 10.1046/j.1365-2265.1999.00719.x [Case-control study, n=385]
  16. Uygur MM, Yoldemir T, Yavuz DG. Thyroid disease in the perimenopause and postmenopause period. Climacteric. 2018 Dec;21(6):542-548. PMID: 30296186 · DOI: 10.1080/13697137.2018.1514004 [Review]
  17. Krassas GE, Tziomalos K, Papadopoulou F, et al. Erectile dysfunction in patients with hyper- and hypothyroidism: how common and should we treat? J Clin Endocrinol Metab. 2008 May;93(5):1815-9. PMID: 18270255 · DOI: 10.1210/jc.2007-2259 [Cohort with control group, n=71 patients]
  18. Kolkhir P, Metz M, Altrichter S, Maurer M. Comorbidity of chronic spontaneous urticaria and autoimmune thyroid diseases: A systematic review. Allergy. 2017 Oct;72(10):1440-1460. PMID: 28407273 · DOI: 10.1111/all.13182 [Systematic Review]
  19. Vrijman C, Kroon MW, Limpens J, et al. The prevalence of thyroid disease in patients with vitiligo: a systematic review. Br J Dermatol. 2012 Dec;167(6):1224-35. PMID: 22860695 · DOI: 10.1111/j.1365-2133.2012.11198.x [Systematic Review, k=48]
  20. Shiri R. Hypothyroidism and carpal tunnel syndrome: a meta-analysis. Muscle Nerve. 2014 Dec;50(6):879-83. PMID: 25204641 · DOI: 10.1002/mus.24453 [Meta-analysis, k=18]
  21. Ness-Abramof R, Nabriski DA, Braverman LE, et al. Prevalence and evaluation of B12 deficiency in patients with autoimmune thyroid disease. Am J Med Sci. 2006 Sep;332(3):119-22. PMID: 16969140 · DOI: 10.1097/00000441-200609000-00004 [Cross-sectional, n=115]
  22. Kahaly GJ, Diana T, Glang J, et al. Thyroid Stimulating Antibodies Are Highly Prevalent in Hashimoto's Thyroiditis and Associated Orbitopathy. J Clin Endocrinol Metab. 2016 May;101(5):1998-2004. PMID: 26964732 · DOI: 10.1210/jc.2016-1220 [Observational study, specialised clinic]
  23. Siegmann EM, Müller HHO, Luecke C, et al. Association of Depression and Anxiety Disorders With Autoimmune Thyroiditis: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2018 Jun;75(6):577-584. PMID: 29800939 · DOI: 10.1001/jamapsychiatry.2018.0190 [Meta-analysis, k=19, n=36,174]
  24. Raber W, Gessl A, Nowotny P, Vierhapper H. Thyroid ultrasound versus antithyroid peroxidase antibody determination: a cohort study of four hundred fifty-one subjects. Thyroid. 2002 Aug;12(8):725-31. PMID: 12225642 · DOI: 10.1089/105072502760258712 [Cohort, n=451]
  25. Rotondi M, de Martinis L, Coperchini F, et al. Serum negative autoimmune thyroiditis displays a milder clinical picture compared with classic Hashimoto's thyroiditis. Eur J Endocrinol. 2014 Jul;171(1):31-6. PMID: 24743395 · DOI: 10.1530/EJE-14-0147 [Case-control study, n=165]
  26. Li D, Radulescu A, Shrestha RT, et al. Association of Biotin Ingestion With Performance of Hormone and Nonhormone Assays in Healthy Adults. JAMA. 2017 Sep;318(12):1150-1160. PMID: 28973622 · DOI: 10.1001/jama.2017.13705 [Crossover study, non-randomised, n=6]
  27. Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf). 1995 Jul;43(1):55-68. PMID: 7641412 · DOI: 10.1111/j.1365-2265.1995.tb01894.x [Cohort, n=2,779]
  28. Huber G, Staub JJ, Meier C, et al. Prospective study of the spontaneous course of subclinical hypothyroidism: prognostic value of thyrotropin, thyroid reserve, and thyroid antibodies. J Clin Endocrinol Metab. 2002 Jul;87(7):3221-6. PMID: 12107228 · DOI: 10.1210/jcem.87.7.8678 [Cohort, prospective, n=82]
  29. Nabhan ZM, Kreher NC, Eugster EA. Hashitoxicosis in children: clinical features and natural history. J Pediatr. 2005 Apr;146(4):533-6. PMID: 15812459 · DOI: 10.1016/j.jpeds.2004.10.070 [Cohort, retrospective, n=69]
  30. Mizokami T, Wu Li A, El-Kaissi S, Wall JR. Stress and thyroid autoimmunity. Thyroid. 2004 Dec;14(12):1047-55. PMID: 15650357 · DOI: 10.1089/thy.2004.14.1047 [Review]
  31. Thayakaran R, Adderley NJ, Sainsbury C, et al. Thyroid replacement therapy, thyroid stimulating hormone concentrations, and long term health outcomes in patients with hypothyroidism: longitudinal study. BMJ. 2019 Sep;366:l4892. PMID: 31481394 · DOI: 10.1136/bmj.l4892 [Cohort, retrospective, n=162,369]
  32. Bolk N, Visser TJ, Nijman J, et al. Effects of evening vs morning levothyroxine intake: a randomized double-blind crossover trial. Arch Intern Med. 2010 Dec;170(22):1996-2003. PMID: 21149757 · DOI: 10.1001/archinternmed.2010.436 [RCT, crossover, n=105]
  33. Benvenga S, Bartolone L, Pappalardo MA, et al. Altered intestinal absorption of L-thyroxine caused by coffee. Thyroid. 2008 Mar;18(3):293-301. PMID: 18341376 · DOI: 10.1089/thy.2007.0222 [Case Series with absorption tests]
  34. Singh N, Singh PN, Hershman JM. Effect of calcium carbonate on the absorption of levothyroxine. JAMA. 2000 Jun;283(21):2822-5. PMID: 10838651 · DOI: 10.1001/jama.283.21.2822 [Cohort, prospective, n=20]
  35. Campbell NR, Hasinoff BB, Stalts H, et al. Ferrous sulfate reduces thyroxine efficacy in patients with hypothyroidism. Ann Intern Med. 1992 Dec;117(12):1010-3. PMID: 1443969 · DOI: 10.7326/0003-4819-117-12-1010 [Uncontrolled clinical study, n=14]
  36. Centanni M, Gargano L, Canettieri G, et al. Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N Engl J Med. 2006 Apr;354(17):1787-95. PMID: 16641395 · DOI: 10.1056/NEJMoa043903 [Clinical study, n=248]
  37. Wiesner A, Gajewska D, Paśko P. Levothyroxine Interactions with Food and Dietary Supplements-A Systematic Review. Pharmaceuticals (Basel). 2021 Mar;14(3):206. PMID: 33801406 · DOI: 10.3390/ph14030206 [Systematic Review, 63 studies]
  38. Holm LE, Blomgren H, Löwhagen T. Cancer risks in patients with chronic lymphocytic thyroiditis. N Engl J Med. 1985 Mar;312(10):601-4. PMID: 3838363 · DOI: 10.1056/NEJM198503073121001 [Cohort, n=829]
  39. Resende de Paiva C, Grønhøj C, Feldt-Rasmussen U, von Buchwald C. Association between Hashimoto's Thyroiditis and Thyroid Cancer in 64,628 Patients. Front Oncol. 2017;7:53. PMID: 28443243 · DOI: 10.3389/fonc.2017.00053 [Meta-analysis, 36 studies, n=64,628]
  40. German Centre for Cancer Registry Data (Zentrum für Krebsregisterdaten, ZfKD) at the Robert Koch Institute. Schilddrüsenkrebs (ICD-10 C73), Datenjahr 2022 (Thyroid cancer, data year 2022). krebsdaten.de, as of 14 October 2024. krebsdaten.de [Official document]
  41. Dhillon-Smith RK, Middleton LJ, Sunner KK, et al. Levothyroxine in Women with Thyroid Peroxidase Antibodies before Conception. N Engl J Med. 2019 Apr;380(14):1316-1325. PMID: 30907987 · DOI: 10.1056/NEJMoa1812537 [RCT, n=952]
  42. Boelaert K, Newby PR, Simmonds MJ, et al. Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am J Med. 2010 Feb;123(2):183.e1-9. PMID: 20103030 · DOI: 10.1016/j.amjmed.2009.06.030 [Cross-sectional, multicentre, n=3,286]
  43. Roy A, Laszkowska M, Sundström J, et al. Prevalence of Celiac Disease in Patients with Autoimmune Thyroid Disease: A Meta-Analysis. Thyroid. 2016 Jul;26(7):880-90. PMID: 27256300 · DOI: 10.1089/thy.2016.0108 [Meta-analysis, n=6,024]
  44. Nederstigt C, Uitbeijerse BS, Janssen LGM, et al. Associated auto-immune disease in type 1 diabetes patients: a systematic review and meta-analysis. Eur J Endocrinol. 2019 Feb;180(2):135-144. PMID: 30508413 · DOI: 10.1530/EJE-18-0515 [Meta-analysis, 180 studies, n=293,889]
  45. Cellini M, Santaguida MG, Virili C, et al. Hashimoto's Thyroiditis and Autoimmune Gastritis. Front Endocrinol (Lausanne). 2017;8:92. PMID: 28491051 · DOI: 10.3389/fendo.2017.00092 [Review]
  46. Brix TH, Kyvik KO, Hegedüs L. A population-based study of chronic autoimmune hypothyroidism in Danish twins. J Clin Endocrinol Metab. 2000 Feb;85(2):536-9. PMID: 10690851 · DOI: 10.1210/jcem.85.2.6385 [Twin study, 2,945 pairs]
  47. Hansen PS, Brix TH, Iachine I, et al. The relative importance of genetic and environmental effects for the early stages of thyroid autoimmunity: a study of healthy Danish twins. Eur J Endocrinol. 2006 Jan;154(1):29-38. PMID: 16381988 · DOI: 10.1530/eje.1.02060 [Twin study, n=1,372]
  48. van Zuuren EJ, Albusta AY, Fedorowicz Z, et al. Selenium supplementation for Hashimoto's thyroiditis. Cochrane Database Syst Rev. 2013 Jun;2013(6):CD010223. PMID: 23744563 · DOI: 10.1002/14651858.CD010223.pub2 [Systematic Review, 4 RCTs, n=463]
  49. Huwiler VV, Maissen-Abgottspon S, Stanga Z, et al. Selenium Supplementation in Patients with Hashimoto Thyroiditis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Thyroid. 2024 Mar;34(3):295-313. PMID: 38243784 · DOI: 10.1089/thy.2023.0556 [Meta-analysis, 35 RCTs]
  50. Larsen C, Winther KH, Cramon PK, et al. Selenium supplementation and placebo are equally effective in improving quality of life in patients with hypothyroidism. Eur Thyroid J. 2024 Feb;13(1):e230175. PMID: 38215286 · DOI: 10.1530/ETJ-23-0175 [RCT, n=412]
  51. Stranges S, Marshall JR, Natarajan R, et al. Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Ann Intern Med. 2007 Aug;147(4):217-23. PMID: 17620655 · DOI: 10.7326/0003-4819-147-4-200708210-00175 [RCT, secondary analysis, n=1,202]
  52. Hahn J, Cook NR, Alexander EK, et al. Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial. BMJ. 2022 Jan;376:e066452. PMID: 35082139 · DOI: 10.1136/bmj-2021-066452 [RCT, n=25,871]
  53. Tang J, Shan S, Li F, Yun P. Effects of vitamin D supplementation on autoantibodies and thyroid function in patients with Hashimoto's thyroiditis: A systematic review and meta-analysis. Medicine (Baltimore). 2023 Dec;102(52):e36759. PMID: 38206745 · DOI: 10.1097/MD.0000000000036759 [Meta-analysis, 12 RCTs, n=862]
  54. Hu S, Rayman MP. Multiple Nutritional Factors and the Risk of Hashimoto's Thyroiditis. Thyroid. 2017 May;27(5):597-610. PMID: 28290237 · DOI: 10.1089/thy.2016.0635 [Review]
  55. Garofalo V, Condorelli RA, Cannarella R, et al. Relationship between Iron Deficiency and Thyroid Function: A Systematic Review and Meta-Analysis. Nutrients. 2023 Nov;15(22):4790. PMID: 38004184 · DOI: 10.3390/nu15224790 [Meta-analysis, 10 cross-sectional studies]
  56. Piticchio T, Frasca F, Malandrino P, et al. Effect of gluten-free diet on autoimmune thyroiditis progression in patients with no symptoms or histology of celiac disease: a meta-analysis. Front Endocrinol (Lausanne). 2023;14:1200372. PMID: 37554764 · DOI: 10.3389/fendo.2023.1200372 [Meta-analysis, 4 studies, n=87]
  57. Araújo EMQ, Coutinho-Lima CRO, Sousa AS, et al. Effects of Gluten-Free Diet in Non-Celiac Hashimoto's Thyroiditis: A Systematic Review and Meta-Analysis. Nutrients. 2025 Oct;17(21):3437. PMID: 41228508 · DOI: 10.3390/nu17213437 [Meta-analysis, 3 RCTs, n=110]
Transparency on the evidence: where the data are thin
  1. I have not found a study that defines or measures a “Hashimoto's flare”. The data on hashitoxicosis come from a paediatric cohort with 8 affected children and cannot be extrapolated to adults.
  2. For commercial home test kits I found no validation study. This is a statement about the state of the literature at the time of research, not an assessment of individual providers.
  3. Symptoms in subclinical hypothyroidism: Carlé and TRUST found no difference, while many affected people experience it differently. TRUST applies only to people aged 65 and over with a mildly raised TSH.
  4. The three frequency figures come from different populations and decades (NHANES III 1988 to 1994, a worldwide meta-analysis with high heterogeneity) and cannot be combined. The 6 percent orbitopathy comes from a specialised clinic, the 14.3 percent associated conditions from a clinic sample based on self-report.
  5. For risk factors, Whickham reports odds ratios, not annual risks per finding group. The abstract only gives incidence rates per 1,000 survivors per year for women and men. Frequently quoted percentages per year for individual finding groups appear only in the full text, which could not be checked, and were not adopted.
  6. The intake studies are small (coffee with few people, calcium 20, iron 14). The stomach acid data come from people with nodular goitre and a lower TSH target.
  7. Guidelines differ on TSH targets (DEGAM 0.4 to 4.0, ETA 0.4 to 2.5, before fertility treatment below 2.5). I have not found a randomised trial showing a patient-relevant advantage of any one target outside pregnancy.
  8. The individual recommendations of the ATA 2026 guideline were not accessible in full text for this article and are therefore not quoted verbatim. Only its scope, methodology and the authors' statement on evidence quality have been adopted.
  9. Cancer risk: the cohort by Holm and colleagues is based on cytological diagnoses from 1959 to 1978 with registry follow-up until 1981. The meta-analysis by Resende de Paiva and colleagues gives only relative risks in its abstract, no absolute case numbers. The German cancer registry figures describe the general population and are therefore not combined with these relative risks.
  10. Selenium, vitamin D, gluten: the meta-analyses mainly measure lab values. Patient-relevant endpoints come mainly from CATALYST, with no difference from placebo. The vitamin D meta-analysis includes calcitriol, and the newest gluten meta-analysis covers only 110 people.
  11. Iron and the thyroid: the association comes from cross-sectional studies with extremely high heterogeneity. No ferritin target can be derived from this; my assessment of it is marked as a clinical observation.
  12. What is deliberately not included here: no dose recommendation for levothyroxine, selenium, vitamin D or iron, no intake schedule, and no advice to change levothyroxine, T3, natural thyroid preparations, antithyroid drugs, acid blockers, calcium or iron products on your own. All dose information is study data. German guideline texts (DEGAM) are translated into English; English guideline texts are paraphrased.

Have questions or want to book an appointment?

We'd be happy to advise you personally at our practice.

Book appointment